Intravenous foscarnet with topical cidofovir for chronic refractory genital herpes in a patient with AIDS

Agnes Usoro, Alfreda Batts, Juan Sarria

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Few case reports have documented the use of topical cidofovir for refractory genital herpes simplex virus (HSV) ulcers in human immunodeficiency virus (HIV) infected patients. This drug formulation lacks a standardized concentration or even a procedural outline as to how it should be compounded. We aim to discuss the utilization of topical cidofovir in addition to presenting a procedural means of compounding it for treatment of refractory genital HSV ulcers. Our patient completed 21 days of intravenous foscarnet and 13 days of topical cidofovir with clinical improvement in the penile and scrotal ulcers. Genital herpes is a concern in patients with HIV because it generally manifests as a persistent infection. Physicians should be aware that when patients fail to respond to the conventional treatment regimens for genital HSV in a timely manner, other options are available, such as topical cidofovir as an adjuvant to systemic antivirals.

Original languageEnglish (US)
JournalJournal of Investigative Medicine High Impact Case Reports
Volume3
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Foscarnet
Herpes Genitalis
Viruses
Refractory materials
Acquired Immunodeficiency Syndrome
AIDS
Simplexvirus
utilization
physician
Ulcer
drug
lack
HIV
Drug Compounding
Antiviral Agents
Physicians
cidofovir
Therapeutics
Infection

Keywords

  • Aids
  • Cidofovir
  • Foscarnet
  • Genital herpes
  • Genital ulcer
  • Herpes
  • Hiv
  • Wound care

ASJC Scopus subject areas

  • Epidemiology
  • Safety, Risk, Reliability and Quality
  • Safety Research

Cite this

@article{f84c6cdb7b474d4f9d68244a9782c6ff,
title = "Intravenous foscarnet with topical cidofovir for chronic refractory genital herpes in a patient with AIDS",
abstract = "Few case reports have documented the use of topical cidofovir for refractory genital herpes simplex virus (HSV) ulcers in human immunodeficiency virus (HIV) infected patients. This drug formulation lacks a standardized concentration or even a procedural outline as to how it should be compounded. We aim to discuss the utilization of topical cidofovir in addition to presenting a procedural means of compounding it for treatment of refractory genital HSV ulcers. Our patient completed 21 days of intravenous foscarnet and 13 days of topical cidofovir with clinical improvement in the penile and scrotal ulcers. Genital herpes is a concern in patients with HIV because it generally manifests as a persistent infection. Physicians should be aware that when patients fail to respond to the conventional treatment regimens for genital HSV in a timely manner, other options are available, such as topical cidofovir as an adjuvant to systemic antivirals.",
keywords = "Aids, Cidofovir, Foscarnet, Genital herpes, Genital ulcer, Herpes, Hiv, Wound care",
author = "Agnes Usoro and Alfreda Batts and Juan Sarria",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/2324709615621095",
language = "English (US)",
volume = "3",
journal = "Journal of Investigative Medicine High Impact Case Reports",
issn = "2324-7096",
publisher = "Sage Publications",
number = "4",

}

TY - JOUR

T1 - Intravenous foscarnet with topical cidofovir for chronic refractory genital herpes in a patient with AIDS

AU - Usoro, Agnes

AU - Batts, Alfreda

AU - Sarria, Juan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Few case reports have documented the use of topical cidofovir for refractory genital herpes simplex virus (HSV) ulcers in human immunodeficiency virus (HIV) infected patients. This drug formulation lacks a standardized concentration or even a procedural outline as to how it should be compounded. We aim to discuss the utilization of topical cidofovir in addition to presenting a procedural means of compounding it for treatment of refractory genital HSV ulcers. Our patient completed 21 days of intravenous foscarnet and 13 days of topical cidofovir with clinical improvement in the penile and scrotal ulcers. Genital herpes is a concern in patients with HIV because it generally manifests as a persistent infection. Physicians should be aware that when patients fail to respond to the conventional treatment regimens for genital HSV in a timely manner, other options are available, such as topical cidofovir as an adjuvant to systemic antivirals.

AB - Few case reports have documented the use of topical cidofovir for refractory genital herpes simplex virus (HSV) ulcers in human immunodeficiency virus (HIV) infected patients. This drug formulation lacks a standardized concentration or even a procedural outline as to how it should be compounded. We aim to discuss the utilization of topical cidofovir in addition to presenting a procedural means of compounding it for treatment of refractory genital HSV ulcers. Our patient completed 21 days of intravenous foscarnet and 13 days of topical cidofovir with clinical improvement in the penile and scrotal ulcers. Genital herpes is a concern in patients with HIV because it generally manifests as a persistent infection. Physicians should be aware that when patients fail to respond to the conventional treatment regimens for genital HSV in a timely manner, other options are available, such as topical cidofovir as an adjuvant to systemic antivirals.

KW - Aids

KW - Cidofovir

KW - Foscarnet

KW - Genital herpes

KW - Genital ulcer

KW - Herpes

KW - Hiv

KW - Wound care

UR - http://www.scopus.com/inward/record.url?scp=85028248927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028248927&partnerID=8YFLogxK

U2 - 10.1177/2324709615621095

DO - 10.1177/2324709615621095

M3 - Article

VL - 3

JO - Journal of Investigative Medicine High Impact Case Reports

JF - Journal of Investigative Medicine High Impact Case Reports

SN - 2324-7096

IS - 4

ER -